- Home
- BSBK vs CNTB Comparison
BSBK vs CNTB Comparison
Compare BSBK & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSBK | CNTB |
|---|---|---|
| Founded | 1893 | 2012 |
| Country | United States | United States |
| Employees | 57 | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.9M | 135.7M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BSBK | CNTB |
|---|---|---|
| Price | $9.06 | $2.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 9.5K | ★ 324.7K |
| Earning Date | 05-12-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 200.00 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $151.33 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.10 | $1.23 |
| 52 Week High | $9.55 | $3.82 |
Technical Indicators
Market Signals| Indicator | BSBK | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 56.47 | 62.11 |
| Support Level | $8.86 | $2.27 |
| Resistance Level | $9.24 | $2.64 |
| Average True Range (ATR) | 0.18 | 0.14 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 38.63 | 78.10 |
Price Performance
Historical ComparisonAbout BSBK Bogota Financial Corp.
Bogota Financial Corp is a New Jersey-based bank. It offers personal and business banking services such as savings, certificates of deposits, online banking, loans, and many more. The Bank generally grants residential, commercial, and consumer loans to, and accepts deposits from, customers in New Jersey. The Company operates one reportable segment of business, retail banking. Through its community banking segment, the Company provides a broad range of retail and commercial banking services.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.